In-San Kim Australia and New Zealand Society for Extracellular Vesicles Conference 2023

In-San Kim

In-San Kim is a KIST Fellow of the Biomedical Research Institute at the Korea Institute of Science and Technology, as well as a professor at the KU-KIST Graduate School of Converging Science and Technology, Korea University. He obtained his M.D. and Ph.D. degrees from Kyungpook National University (KNU) Medical School and completed postdoctoral training at the Department of Molecular Genetics of M. D. Anderson Cancer Center in Dr. Benoit deCrombrugghe's laboratory before becoming a full professor at KNU Medical School. Kim founded the Korean Society of Matrix Biology and served as its first president, as well as the president of the Korean Society of Molecular Imaging from 2013 to 2015, the Korean Society of Cell Biology from 2007 to 2009, and the Korea Society of Biochemistry and Molecular Biology from 2021 to 2022. He is a fellow of the Korean Academy of Science & Technology and a member of the National Academy of Medical Science of Korea. Kim has served on several government committees, including the Health Technology Policy Committee of the Ministry of Health & Welfare, the Advisory Board of the Korea National Institute of Health, and the Bio-Health Division of the National Science & Technology Commission. His research focuses on cell adhesion molecules and extracellular matrix proteins and their roles in chronic diseases, particularly cancer. Kim identified stabilin proteins as a phosphatidylserine receptor critical for the clearance of apoptotic cells and has expanded his research interests to include the development of drugs based on nanocage proteins and exosomes, particularly harnessing the immune system for cancer control. He has published over 320 peer-reviewed papers and filed several patents. Kim has received numerous awards, including the Hyeoksin Medal for Science and Technology Merit from the Korean Government in 2022 and the 1st Lim Sung Ki Researcher Award in 2022. He recently founded ShiftBio Inc., a startup company focused on developing exosome-based therapeutics.